These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17303473)

  • 1. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?
    Ernsberger P; Koletsky RJ
    Curr Opin Pharmacol; 2007 Apr; 7(2):140-5. PubMed ID: 17303473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PPARgamma-activating properties of angiotensin receptor blockers].
    Ando H; Fujimura A
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV protease inhibitors activate the adipocyte renin angiotensin system.
    Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
    Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK
    Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irbesartan: review of pharmacology and comparative properties.
    Adams MA; Trudeau L
    Can J Clin Pharmacol; 2000; 7(1):22-31. PubMed ID: 10822210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiotensin-II receptor blockers].
    Metelitsa VI
    Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin II type 1 receptor blockers.
    Burnier M
    Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Grossman E; Messerli FH; Neutel JM
    Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
    [No Abstract]   [Full Text] [Related]  

  • 11. [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
    Winkler G; Jermendy G; Matos L
    Orv Hetil; 2003 Sep; 144(36):1763-8. PubMed ID: 14579673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
    Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
    Ariyoshi Y; Mizumoto K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin receptor antagonists.
    Wong W; Howes L
    Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
    Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
    Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
    Ellis ML; Patterson JH
    Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Irbesartan: a new possibility in the treatment of hypertension].
    Rapi J
    Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
    Michel MC; Brunner HR; Foster C; Huo Y
    Pharmacol Ther; 2016 Aug; 164():1-81. PubMed ID: 27130806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
    Burnier M; Buclin T; Biollaz J; Nussberger J; Waeber B; Brunner HR
    Kidney Int Suppl; 1996 Jun; 55():S24-9. PubMed ID: 8743506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.